Where should pharma invest to remain at the forefront of healthcare?
The online conversations about breast cancer drug Kadcyla before it was approved by NICE.
New technologies coming along to disrupt the pharma industry.
How do the countries of the UK fund cancer drugs today, and do they have the right approaches?
Developments that promise to improve clinical research in Brazil.
Assessing the global challenges inhibiting immuno-oncology market access.
Who could influence the makeup of the new PPRS?